Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.

Trial Profile

A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms meriT-V
  • Sponsors Meril Life Sciences

Most Recent Events

  • 25 Sep 2018 Primary endpoint (To assess in-stent Late Lumen Loss) has been met, according to the results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
  • 25 Sep 2018 Results assessing 12-month clinical outcomes, presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
  • 03 Apr 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top